# Blood Compartment - Gap Analysis & Roadmap

## Darwin PBPK Platform v2.5.0
**Date:** 2025-12-05

---

## Executive Summary

The Darwin PBPK Platform has **60-65% completeness** of a standard PBPK blood compartment, with **exceptionally advanced** WBC and fractal dynamics modeling but **critical gaps** in platelets and coagulation factors.

---

## Current Implementation Status

### Fully Implemented (GREEN)

| Component | Status | Files |
|-----------|--------|-------|
| Plasma (free drug) | ✅ Complete | `compartment_models.jl` |
| Albumin/AGP binding | ✅ Complete | `blood_work_integration.jl` |
| Hematocrit effects | ✅ Complete | `patient_profile.jl` |
| Blood flows (14 organs) | ✅ Complete | `ode_solver.jl` |
| Blood-to-plasma ratio | ✅ Complete | `fractal_blood.jl` |
| Blood-brain barrier | ✅ Complete | `brain_kpuu*.jl` |
| Lymphatic circulation | ✅ Complete | `lymphatic_absorption_model.jl` |
| **WBC (7 subpopulations)** | ✅✅ Advanced | `white_blood_cells.jl` |
| **Fractal dynamics (CTRW)** | ✅✅ Advanced | `fractal_blood.jl` |
| **SAM-3 morphology** | ✅✅ Advanced | `leukocyte_diagnostics.jl` |

### Partially Implemented (YELLOW)

| Component | Status | Gap |
|-----------|--------|-----|
| RBC compartment | ⚠️ Basic | Missing transporters |
| Protein binding | ⚠️ Basic | Missing lipoproteins |
| Pathophysiology | ⚠️ Partial | Limited disease states |

### Not Implemented (RED)

| Component | Severity | Impact |
|-----------|----------|--------|
| **Platelets** | 🔴 CRITICAL | Blocks anticoagulant PBPK |
| **Coagulation factors** | 🔴 CRITICAL | Blocks anticoagulant PBPK |
| RBC transporters | 🟠 HIGH | Limits antimalarial accuracy |
| Immunoglobulins | 🟠 HIGH | Blocks mAb/ADC PBPK |
| Lipoproteins | 🟡 MEDIUM | Limits statin accuracy |

---

## Priority Roadmap

### TIER 1: Critical (1-2 weeks)

**Goal:** Enable anticoagulant/antiplatelet drug PBPK

#### 1.1 Platelet Compartment (`platelets.jl`)

```julia
struct PlateletCompartment
    count::Float64              # 150-400 K/μL
    volume_per_cell::Float64    # 7.5 fL mean
    partition_coeff::Float64    # Drug-specific (0.5-3.0)
    binding_capacity::Float64   # Bmax
    binding_affinity::Float64   # Kd
    
    # Granules
    dense_granule_fraction::Float64  # 0.05 (serotonin, ADP)
    alpha_granule_fraction::Float64  # 0.10 (VEGF, fibrinogen)
    
    # Dynamics
    activation_state::Float64   # 0-1 (affects binding)
    turnover_rate::Float64      # 8-10 days lifespan
end
```

**Drugs enabled:** Clopidogrel, prasugrel, ticagrelor, aspirin PD/PK

#### 1.2 Coagulation Factors (`coagulation.jl`)

```julia
struct CoagulationFactors
    # Zymogens (inactive)
    prothrombin::Float64        # Factor II: 70-140 μg/mL
    factor_VII::Float64         # 0.5-1.5 μg/mL
    factor_IX::Float64          # 3-5 μg/mL
    factor_X::Float64           # 8-10 μg/mL
    
    # Active factors (generated during clotting)
    thrombin::Float64           # Factor IIa
    factor_Xa::Float64          # Target of DOACs
    
    # Fibrinogen → Fibrin
    fibrinogen::Float64         # 2-4 g/L
    
    # Vitamin K-dependent synthesis rate
    synthesis_rate::Float64     # Affected by warfarin
    
    # Disease adjustments
    liver_function::Float64     # 0-1 (affects synthesis)
end
```

**Drugs enabled:** 
- Warfarin (vitamin K antagonist)
- Apixaban, rivaroxaban (Factor Xa inhibitors)
- Dabigatran (direct thrombin inhibitor)

---

### TIER 2: High Priority (3-4 weeks)

**Goal:** Support major drug classes

#### 2.1 RBC Transporters (`rbc_transport.jl`)

```julia
struct RBCTransporters
    # Anion exchanger
    band3_vmax::Float64         # Cl⁻/HCO₃⁻ exchange
    band3_km::Float64
    
    # Organic transporters
    oat_vmax::Float64           # Organic anion
    oct_vmax::Float64           # Organic cation
    
    # pH gradient
    cytoplasm_ph::Float64       # 7.22
    external_ph::Float64        # 7.40
    
    # Hemoglobin binding
    hb_concentration::Float64   # 330 g/L in RBC
    hb_drug_kd::Dict{String, Float64}
end
```

**Drugs enabled:** Chloroquine, quinine, metformin (high RBC partition)

#### 2.2 Immunoglobulin Binding (`immunoglobulins.jl`)

```julia
struct ImmunoglobulinBinding
    igg_total::Float64          # ~12 g/L (4 subtypes)
    igm::Float64                # ~1.5 g/L
    iga::Float64                # ~2.5 g/L
    
    # For mAb/ADC
    target_antigen_conc::Float64
    kon::Float64                # Association rate
    koff::Float64               # Dissociation rate
    
    # Fc receptor interactions
    fcgamma_r::Float64          # FcγR expression
end
```

**Drugs enabled:** Rituximab, trastuzumab, pembrolizumab, ADCs

#### 2.3 Lipoprotein Binding (`lipoproteins.jl`)

```julia
struct LipoproteinBinding
    hdl::Float64                # 40-60 mg/dL
    ldl::Float64                # 100-130 mg/dL
    vldl::Float64               # 10-30 mg/dL
    
    # Apolipoproteins
    apoa1::Float64              # HDL component
    apob::Float64               # LDL component
    
    # Drug binding
    drug_kp_hdl::Float64
    drug_kp_ldl::Float64
end
```

**Drugs enabled:** Statins, cyclosporine, amiodarone (high lipophilicity)

---

### TIER 3: Medium Priority (4-6 weeks)

#### 3.1 Blood Pathophysiology (`blood_pathophysiology.jl`)

```julia
# Disease state adjustments
function apply_liver_disease!(blood::BloodCompartment, severity::Float64)
    blood.albumin *= (1 - 0.5 * severity)
    blood.coagulation.synthesis_rate *= (1 - 0.7 * severity)
    blood.coagulation.fibrinogen *= (1 - 0.3 * severity)
end

function apply_renal_disease!(blood::BloodCompartment, gfr::Float64)
    blood.agp *= 1 + 0.5 * (1 - gfr/90)  # AGP increases
    blood.uremic_binding_effect = 1 - 0.3 * (1 - gfr/90)
end

function apply_sepsis!(blood::BloodCompartment)
    blood.agp *= 2.0  # Acute phase response
    blood.wbc.neutrophils.count *= 10  # Already implemented
    blood.platelets.activation_state = 0.8
end
```

#### 3.2 Advanced Capillary Dynamics (`capillary_dynamics.jl`)

```julia
struct CapillaryDynamics
    # Starling forces
    hydrostatic_pressure::Float64   # mmHg
    oncotic_pressure::Float64       # Protein-dependent
    
    # Permeability
    reflection_coefficient::Float64 # σ (0-1)
    hydraulic_conductivity::Float64 # Lp
    
    # Surface area
    capillary_density::Float64      # Tissue-specific
    effective_area::Float64         # Recruitment-dependent
end
```

---

## Comparative Analysis

### Before (Current)

```
Blood Compartment Completeness:
████████████░░░░░░░░ 60%

WBC Detail:       ████████████████████ 100%
RBC Detail:       ████████░░░░░░░░░░░░ 40%
Platelets:        ░░░░░░░░░░░░░░░░░░░░ 0%
Coagulation:      ░░░░░░░░░░░░░░░░░░░░ 0%
Protein Binding:  ██████████░░░░░░░░░░ 50%
Blood Flow:       ████████████████████ 100%
Fractal Dynamics: ████████████████████ 100%
```

### After Tier 1 Implementation

```
Blood Compartment Completeness:
████████████████░░░░ 80%

WBC Detail:       ████████████████████ 100%
RBC Detail:       ████████░░░░░░░░░░░░ 40%
Platelets:        ████████████████████ 100%
Coagulation:      ████████████████████ 100%
Protein Binding:  ██████████░░░░░░░░░░ 50%
Blood Flow:       ████████████████████ 100%
Fractal Dynamics: ████████████████████ 100%
```

### After Tier 2 Implementation

```
Blood Compartment Completeness:
██████████████████░░ 90%

WBC Detail:       ████████████████████ 100%
RBC Detail:       ████████████████████ 100%
Platelets:        ████████████████████ 100%
Coagulation:      ████████████████████ 100%
Protein Binding:  ████████████████████ 100%
Blood Flow:       ████████████████████ 100%
Fractal Dynamics: ████████████████████ 100%
```

---

## Drug Classes Enabled by Tier

| Tier | Drug Classes Enabled | Examples |
|------|---------------------|----------|
| Current | Most small molecules | Metformin, ibuprofen |
| Tier 1 | Anticoagulants, antiplatelets | Warfarin, clopidogrel, DOACs |
| Tier 2 | Antimalarials, mAbs, statins | Chloroquine, rituximab, atorvastatin |
| Tier 3 | Complex disease states | ICU patients, liver failure |

---

## Implementation Estimates

| Component | Lines of Code | Time | Complexity |
|-----------|---------------|------|------------|
| Platelets | 100-150 | 3-5 days | Medium |
| Coagulation | 200-250 | 5-7 days | High |
| RBC transporters | 150-200 | 4-6 days | Medium |
| Immunoglobulins | 200-250 | 5-7 days | High |
| Lipoproteins | 100-150 | 3-4 days | Medium |
| Pathophysiology | 150-200 | 4-6 days | Medium |
| Capillary dynamics | 200-300 | 5-8 days | High |

---

## Recommendation

**Immediate Action:** Implement Tier 1 (Platelets + Coagulation)

This will:
1. Enable anticoagulant PBPK (huge clinical need)
2. Increase completeness to 80%
3. Provide foundation for disease modeling (DIC, liver disease)

**Estimated Effort:** 1-2 weeks
**Expected Impact:** Major expansion of drug class coverage

---

## File Structure After Implementation

```
julia-migration/src/DarwinPBPK/
├── fractal_blood.jl                    # CTRW dynamics (existing)
├── compartments/
│   ├── white_blood_cells.jl            # WBC (existing)
│   ├── platelets.jl                    # NEW: Tier 1
│   └── coagulation.jl                  # NEW: Tier 1
├── blood/
│   ├── rbc_transport.jl                # NEW: Tier 2
│   ├── immunoglobulins.jl              # NEW: Tier 2
│   ├── lipoproteins.jl                 # NEW: Tier 2
│   ├── blood_pathophysiology.jl        # NEW: Tier 3
│   └── capillary_dynamics.jl           # NEW: Tier 3
└── image_analysis/
    ├── sam3_integration.jl             # SAM-3 masks (existing)
    └── leukocyte_diagnostics.jl        # ML classifier (existing)
```

---

*Darwin PBPK Platform - Advancing Precision Medicine*
